IVI in the Media
South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?
South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread
Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University
Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions
South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more
The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus
Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.
CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute
ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19
The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge
South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?
The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening
South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world
South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?
South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?
National Geographic | Omicron is dodging the immune system—but boosters show promising signs
Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert
Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It
South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter
South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?
South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2
South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications
South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?
Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light
EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?
South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think
The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19
Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine
Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea
Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines
Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions
The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line
CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things
The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’
ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine
Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim
South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute
Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)
Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)
How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)
Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”
Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?
IVI Holds Inauguration Ceremony for New Director General Dr. Jerome H. Kim
IVI Holds Inauguration Ceremony for
New Director General Dr. Jerome H. Kim
Dignitaries pose for a photo at the inauguration of the IVI Director General at IVI Headquarters on June 22. The event was attended by more than 100 people, including Dr. Jerome Kim (fourth from left, front row); Prof. Adel A. Mahmoud, Chair of the IVI Board of Trustees (third from left, front row); Lars Danielsson, Swedish Ambassador to Korea (third from left, rear row); Mark Lippert (far right, rear row), U.S. Ambassador to Korea; Dr. Gim Chaechun (second from left, front row), Vice Minister of Education; Prof. Sung Nak-in (third from right, front row), President of Seoul National University; and Prof. Cho Dong-sung, President of the Korea Support Committee for IVI.
l Ceremony attended by more than 100 people including donors and partners such as Korean Ministry of Education, Swedish Ambassador to Korea, and the Bill & Melinda Gates Foundation
l Director General Kim urges partners to “Harness science in the interest of society” and calls for continued support, strengthened partnerships in vaccine research to cope with emerging diseases including MERS and Ebola, as well as neglected diseases such as cholera
June 22, Seoul, South Korea - The International Vaccine Institute (IVI) held an inauguration ceremony for its new Director General Jerome H. Kim, M.D., at the IVI headquarters at Seoul National University today. Dr. Kim began his term in March 2015 and will be leading the Seoul-based international organization for the next four years.
Dr. Kim, who has accumulated a wide range of knowledge and experience as a vaccine development expert and HIV research authority, has been spotlighted as the first IVI leader of Korean descent. Dr. Kim’s appointment as IVI’s leader is expected to add significant momentum to the development of the Institute, the first international organization hosted by the Republic of Korea.
The inauguration ceremony was attended by more than 100 people including IVI donors, stakeholders, and partners. Remarks were given by Prof. Adel A. Mahmoud, Chair of IVI’s Board of Trustees and Professor of Molecular Biology at Princeton University in the U.S.; Gim Chae-Chun, Vice Minister of Education of Korea; Ms. Becky Frank, Deputy Director of Strategy Planning & Management for Enteric & Diarrheal Disease (EDD) and Pneumonia from the Bill & Melinda Gates Foundation; H.E. Lars Danielsson, Swedish Ambassador to Korea; Prof. Sung Nak-In, President of Seoul National University; and Prof. Cho Dong-Sung, President of the Korea Support Committee for IVI (KSC).
In his inaugural speech, Dr. Kim stated, “This ceremony is being held at a time when Korea is battling the Middle East Respiratory Syndrome, or MERS, a disease unknown until 2012…like SARS, influenza, and Ebola the spread of these threats is facilitated by something we all take for granted, the necessity, and ease, of international travel…we must engage with energy and purpose: to identify, understand, and control – to develop treatments and work on prevention, and ultimately, a vaccine. Once again, let’s harness science in the interest of society.”
Vice Minister Gim Chae-Chun, said, “In the wake of the recent outbreak of MERS in Korea and last year's Ebola virus epidemic in West Africa, the global community is becoming ever more aware of the importance of developing and distributing vaccines, which is why it is time for the international community to make concerted efforts under the lead of IVI,” adding, “I'm looking forward to seeing IVI boost capacity in vaccine research and take a new leap forward under Director General Kim’s leadership.”
IVI has been collaborating with a number of vaccine manufacturers in several countries through technology transfer and clinical development to help them bring vaccines to licensure and to obtain WHO prequalification (PQ). In Korea, IVI is partnering with SK Chemicals on a new typhoid vaccine and with EuBiologics on an oral cholera vaccine.
“IVI’s vaccine research has been instrumental in helping to reduce the burden of infectious diseases in developing countries. Their support is helping to elevate the global profile of the Korean vaccine industry and research capabilities to have a positive impact on global health, Ms. Becky Frank of the Gates Foundation said. “As Korean companies have become household names globally for electronic consumer goods, cars and others industries, we can easily envision a future where Korea enjoys the same reputation for vaccines.”
Dr. Kim is among the world’s leading authorities in the field of HIV/AIDS vaccine development. He was named one of “The 50 Most Influential People in Vaccines” in 2014 by the vaccine industry organization Vaccine Nation. Prior to joining IVI, Dr. Kim served as Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis at the U.S. Military HIV Research Program (MHRP) and also as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Material Development Activity. He is a Professor of Medicine at the Uniformed Services University of the Health Sciences, and Fellow of the American College of Physicians and the Infectious Diseases Society of America. He received his M.D. from the Yale University School of Medicine.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.
IVI Media Contact:
Tae Kyung Byun
Public Awareness/Advocacy Officer, IVI
Phone: +82-2-872-2801 (Ext. 159)
Burson-Marsteller Korea Contact: